Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy.

Details

Serval ID
serval:BIB_2365C91E7429
Type
Article: article from journal or magazin.
Collection
Publications
Title
Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy.
Journal
Neuroreport
Author(s)
Kanbayashi T., Nishino S., Tafti M., Hishikawa Y., Dement W.C., Mignot E.
ISSN
0959-4965[print], 0959-4965[linking]
Publication state
Published
Issued date
08/1996
Volume
7
Number
12
Pages
1881-1886
Language
english
Notes
Publication types: Journal Article ; Research Support, U.S. Gov't, P.H.S.
Publication Status: ppublish
Abstract
Thalidomide is a sedative hypnotic that was widely used in the 1950s but was withdrawn due to its teratogenic properties. The compound has recently been reintroduced as an immune modulating agent. Thalidomide significantly aggravates canine cataplexy, a pathological manifestation of rapid eye movement (RFM) sleep atonia seen in narcolepsy. This compound also increases REM sleep and slow wave sleep in these animals. In vitro receptor binding and enzyme assays demonstrate that thalidomide does not bind to or enzymatically modulate the neurotransmitter systems reported to be involved in the regulation of cataplexy. Thalidomide may therefore affect cataplexy through its immune modulation properties. Further studies on the mechanisms of action of thalidomide should increase our understanding of the pathophysiology of this disabling disorder.
Keywords
Animals, Binding, Competitive, Cataplexy/chemically induced, Cataplexy/metabolism, Cerebral Cortex/drug effects, Cerebral Cortex/metabolism, Dogs, Dose-Response Relationship, Drug, Narcolepsy/chemically induced, Narcolepsy/metabolism, Sleep/drug effects, Thalidomide/pharmacology
Pubmed
Web of science
Create date
24/01/2008 15:55
Last modification date
20/08/2019 13:01
Usage data